The DOI matches its Crossref record.
Drug price control in Malaysia: a stakeholder analysis
Abstract
Purpose Pharmaceutical pricing has always been a contentious issue around the world. Recently, the Government of Malaysia has proposed for drug price control. This proposal has received backlash from pharmaceutical industry. Therefore in this study, the authors would like to examine the position of various stakeholders on this issue. Design/methodology/approach The authors used Policy Maker software to identify and evaluate the position of the stakeholders, their interest and their power. Next, the authors contextualize the factors that might contribute to the success or failure of the policy using Kingdon's multiple stream analysis. Findings The authors found that the drug price control regulation received mixed reactions from the stakeholders, with the public sector mainly supporting the proposal whereas the private sectors opposing it. The findings indicate that the drug price control proposal have a high chance of success due to strong political will from both the government and the opposition and also strong support from the public and the consumer groups. Practical implications 1. The drug price control proposal received strong political will and strong public support. Thus, it has a high chance of success. 2. The government should be careful in managing concentrated powerful groups. The government should strategically engage with the stakeholders to move them to more positive attitude. 3. The government should avoid backtracking on policies as this will portray critica…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Still being checked.
Research works printed but not linked: 37
- 2003, Pelobian Polisi Awam: Pengaruh Gabungan Persatuan-persatuan Pengguna Malaysia (FOMCA) sebagai Kumpulan Pendesak, Jurnal Komunikasi: Malaysian Journal of Communication, 19, 39
- 2018, Affordability of essential medicine prices in Malaysia's private health sector, Patient Prefer Adherence, 12, 1
- Babar, Z.U.D., Ibrahim, M.I.M., Singh, H., Bukahri, N.I. and Creese, A. (2007), “Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia”, in Harvey, K. (Ed.), PLoS Med, [Internet], Vol. 4 No. 3, p. e82, available at: https://dx.plos.org/10.1371/journal.pmed.0040082. · DOI
- 2017, High drug prices: so who is to blame?, Hospital Pharmacy, 52, 5, 10.1310/hpj5201-5 · DOI
- 2019, The hepatitis C infection in Iran: a policy analysis of agenda-setting using Kingdon's multiple streams framework, Health Research Policy and System, 17, 1
- Bernama, 2020, Kumpulan isi rumah B40, M40, T20 terbahagi pada 10 kategori, Berita Harian
- 2020, Policy transfer processes and renewable energy penetration: a comparative analysis of Peru, Thailand, and Uganda, Sustain Earth, 3, 2, 10.1186/s42055-019-0019-4 · DOI
- 2012, Ambiguity: the challenge of knowing and deciding together, Environmental Science and Policy
- 2013, Why do ideas succeed and fail over time? The role of narratives in policy windows and the case of the London congestion charge, Journal of European Public Policy, 20, 1139, 10.1080/13501763.2013.771090 · DOI
- 2019, How interest groups influence public opinion: arguments matter more than the sources, European Journal of Political Research, 58, 514, 10.1111/1475-6765.12298 · DOI
- European Federation of Pharmaceutical Industries and Associations, 2019, The Pharmaceutical Industry in Figures
- 2015, Shaping the health policy agenda: the case of safe motherhood policy in Vietnam, International Journal of Heal Policy Management, 4, 741
- 2007, Defining strategic communication, International Journal of Strategic Communication, 1, 3, 10.1080/15531180701285244 · DOI
- 2012, A study comparing the retail drug prices between Northern Malaysia and Australia, Journal of Pharmaceutical Health Service Research, 3, 103, 10.1111/j.1759-8893.2011.00080.x · DOI
- 2010, Explaining local policy choices: a multiple streams analysis of municipal emergency management, Canadian Public Administration, 53, 241, 10.1111/j.1754-7121.2010.00128.x · DOI
- 2002, Agenda-setting for the regulation of traditional Chinese medicine in Hong Kong, Asian Journal of Public Administration, 24, 257, 10.1080/02598272.2002.10800403 · DOI
- 2020, Does external reference pricing deliver what it promises? Evidence on its impact at national level, The European Journal of Health Economics, 21, 129, 10.1007/s10198-019-01116-4 · DOI
- 1995, Agendas, alternatives and public policies (ch. 8)
- 2020, Profitability of large pharmaceutical companies compared with other large public companies, JAMA, 323, 834, 10.1001/jama.2020.0442 · DOI
- LIAM,PIAM M (2019), “A joint-press statement by the life insurance association of Malaysia (LIAM), Persatuan Insurans Am Malaysia (PIAM) and Malaysian Takaful Association (MTA)”, [Internet], available at: https://piam.org.my/joint-press-statement-life-insurance-association-malaysia-liam-persatuan-insurans-malaysia-piam-malaysian-takaful-association-mta/.
- 2018, Expanding evaluation to progress strategic communication: beyond message tracking to open listening, International Journal of Strategic Communication, 12, 469, 10.1080/1553118X.2018.1450255 · DOI
- Malaysia Competition Commission, 2017, Market Review on Priority Sector under Competition Act 2010 Pharmaceutical Sector
- 2007, Window of opportunity for intersectoral health policy in Sweden open, half-open or half-shut?, Health Promotion International, 22, 307, 10.1093/heapro/dam028 · DOI
- Ministry of Health Malaysia, 2019, Malaysia National Health Accounts: Health Expenditure Report 1997-2017
- Ministry of Health Malaysia, 2020, Ministry of Health Vision, Mission, Objectives & Role
- 2017, Policy entrepreneurs and problem framing: the case of climate change, Environment and Planning C: Politics and Space, 35, 1362, 10.1177/2399654417708440 · DOI
- PhAMA (2019), “Medicines price control will have negative repercussions”, available at: https://www.malaysiakini.com/letters/494410.
- 1996, PolicyMaker: Computer-Assisted Political Analysis (Software and Manual)
- 2015, Overview of external reference pricing systems in Europe, Journal of Market Access and Health Policy, 3, 27675, 10.3402/jmahp.v3.27675 · DOI
- 2017, Setting performance-based financing in the health sector agenda: a case study in Cameroon, Globalization and Health, 13, 52, 10.1186/s12992-017-0278-9 · DOI
- 2019, Cabinet Approves Drug Price Controls
- 2019, Competition Beats Medicine Price Controls
- The Galen Centre for Health and Social Policy, 2019, Drug Price Controls in Malaysia: Implications and Considerations
- WHO Regional Office for South-East Asia, 2017, Financial Protection in the South-East Asia Region: Determinants and Policy Implications, 19
- 2020, Lobbying expenditures and campaign contributions by the pharmaceutical and health product industry in the United States, 1999-2018, JAMA Internal Medicine, 180, 688, 10.1001/jamainternmed.2020.0146 · DOI
- 2018, Strategic communication: defining the field and its contribution to research and Practice, International Journal of Strategic Communication, 12, 487, 10.1080/1553118X.2018.1493485 · DOI
- 2020, Drug utilization and drug pricing in the private primary healthcare system in malaysia: an employer price control mechanism, Frontiers in Public Health, 8, 1
Cited by
Mahuwi, L., & Israel, B. (2024) · Management Matters · doi:10.1108/manm-07-2023-0027 · Cited by 25
Israel, B. (2023) · International Journal of Health Governance · doi:10.1108/ijhg-03-2023-0028 · Cited by 8
Metadata
- Authors
- Ashraf, A., & Ong, S. C.
- Affiliations
- Universiti Sains Malaysia (MY)
- Venue
- International Journal of Health Governance
- Publisher
- Emerald
- Published
- 2021-08-24
- Volume
- 26
- Issue
- 4
- Pages
- 333-347
- ISSN
- 2059-4631 (ISSN-L)
- OpenAlex
- W3195182961
- Cited by
- 12
- References
- 0
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 6 · 2022: 3 · 2021: 1
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.emerald.com/insight/site-policies (tdm)
- Locations
- International Journal of Health Governance (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Global Public Health Policies and Epidemiology
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Healthcare Systems and Reforms
- Keywords
- drug price regulation, drug pricing, stakeholder analysis, Malaysia, pharmaceutical industry opposition, public sector support, consumer groups, political will, health policy, policy success factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
